CPHI China - 21 to 23 June 2011- CPHI China Information - CPHI China Shanghai.

CPHI China - June 2011, Shanghai, China Information :

CPHI China @ Shanghai New Internation Expo Center (SNIEC)
Date @ 21 June 2011 to 23 June 2011
City @ Shanghai
Country @ China.

CPHI China - June 2011: Description:
CPhI China is a committed exhibition for the Medical & Pharmaceutical industry and has been organized in China since its launch in 2001. The latest edition of the fair has been organized by UBM Asia Limited and will start from 21st June 2011. Last year’s event was attended by 26, 547 pharma professionals and included 7, 806 international visitors. With such a large visitor base, this trade fair has been widely acclaimed as one of the best in the Pharmaceutical industry. CPhI China mirrors the growth of Chinese industries over the last decade and it showcases its excellence in the medical and pharma industry. With China’s initiative in the R&D and innovation, this fair opens up the doors for international exhibitors to affect an eager Chinese market. This 3 day event will happen at Shanghai New International Expo Centre.

Highlights of CPHI China - 2011

• Trading with massive and untapped Chines market will be possible at the event.
• Exhibit in front of global leaders and decision makers.
• Opportunity to build important relations and partnership with other pharma companies.
• Face to face meeting with potential customers.
• Over 1, 600 exhibitors and 23, 000 visitors.

For More Information Please Click Here or Use this link

http://www.cphi-china.com/

Optimer Pharma antibacterial drug gets Food and Drug Administration (FDA) favorable reception

Optimer Pharmaceuticals, a finder, developer and commercializer of hospital specialty products, has received the US Food and Drug Administration's (FDA) approval for its antibacterial drug Dificid (fidaxomicin) pills.

Dificid tablets are pointed for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age or older.

The FDA approval was given on the basis of the positive results from II Phase 3 randomized, multi-center, double-blinded trials involved 1,164 patients suffering from CDAD that compared Dificid with vancomycin, a usual antibiotic drug used to treat CDAD.

The results of the trial suggested that Dificid was higher-up to vancomycin in sustaining clinical response through 25 days on the far side the end of treatment.

Optimer president and chief executive officer(CEO) Pedro Lichtinger said the clinical development program for DIFICID was designed to address one of the greatest challenges in managing CDAD, disease recurrence.

"We are proud to provide the medical community and patients with an effective treatment proven to produce confirmed clinical response in CDAD, and are now moving into the commercialization stage where we'll partner with physicians and health systems to ensure that DIFICID reaches patients in urgent demand of an important new treatment option," Lichtinger said.http://www.pharmaexhibtion.blogspot.com